LUMBY, British Columbia, April 19 /PRNewswire-FirstCall/ -- avVaa World Health Care Products, Inc. , a biotech company offering global customers therapeutic skin and health care products, is pleased to announce it has filed its SEC form 10-QSB quarterly report containing financial and operating results for the quarter ended February 28, 2006.
For its third quarter of 2006, avVaa reports a loss for the three months ended February 28, 2006 of $1,137,232 ($0.03 per share) compared to a loss of $468,991 in the comparable three months ended February 28, 2005 ($0.02 per share).
CEO Jack Farley said, “While our third quarter numbers reflect the high cost of interest relating to the convertible notes issued and selling, general and administrative expenses, we have made a number of strategic in-roads with our products during the period. During the quarter, avVaa began initial market testing of our human skin care line in a strategic U.S. market and introduced our newest line of pet and equine products formulated for the unique needs of animals. These products are now being distributed through a number of venues in Canada and we expect to launch in the U.S. market by the end of the year.”
Farley continued, “Management remains focused on strategic marketing and distribution while establishing crucial relationships to ensure long term success for our growing company.”
About avVaa World Health Care Products
avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers.
avVaa’s patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin line of skin care products through mass, food and drug channels in the United States and globally. The Company’s secondary line of equine and pet care related products are already being distributed throughout all of Canada. For more information, visit: http://www.avvaa.com or http://www.otcfn.com/avvw.
For additional information on avVaa contact Jack Farley CEO/President, at 1-866-772-8822 or visit: http://www.avvaa.com or http://www.otcfn.com/avvw.
Investor Relations: Merle Goertz (West Coast) of avVaa World
Health Care Products, 1-604-688-2349; or Richard McCaffrey of OTC Financial Network, 1-781-444-6100 ext. 625
Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward- looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of avVaa World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
avVaa World Health Care Products
CONTACT: Merle Goertz of avVaa World Health Care Products,+1-604-688-2349; or Richard McCaffrey of OTC Financial Network,+1-781-444-6100 ext. 625
Web site: http://www.avvaa.com/
